Boehringer trial pairs obrixtamig with Zai Lab's ZL-1310 in SCLC and neuroendocrine cancers
Boehringer Ingelheim registered a Phase Ib/II study testing obrixtamig plus ZL-1310, with Zai Lab as collaborator, in small cell lung cancer and related neuroendocrine tumors.
The week's single notable item is a newly recruiting Boehringer Ingelheim trial combining two investigational cancer drugs.
- "DAREON-36" is a Phase Ib/II, open-label trial sponsored by Boehringer Ingelheim with Zai Lab as collaborator, testing obrixtamig combined with ZL-1310 in patients with advanced small cell lung cancer or other neuroendocrine cancers. The study is recruiting, with an estimated enrollment of 60 participants1. In Part 2, the regimen is extended to include a checkpoint inhibitor, and Part 2 is only open to people with advanced small cell lung cancer.1 The trial's primary outcomes include the occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period1 in Part 1, and in Part 2, PFS rate at 6 months.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.